Get SEC filing alerts via email and in your feed for AGENUS INC
AGEN
AGENUS INC
About AGENUS INC
Agenus Inc. is a clinical-stage biotechnology company focused on immuno-oncology, developing therapies that activate the immune system against cancer. Its diverse pipeline includes immune-modulatory antibodies and adoptive cell therapies, with key products like botensilimab and balstilimab in advanced trials. Targeting a significant market opportunity, Agenus aims to enhance treatment outcomes through innovative combination therapies and strategic partnerships, while also advancing vaccine adjuvants via its subsidiary, SaponiQx.
This description was generated via AI from an annual report.
Updated 8 months ago.